First-line CDK4/6 inhibitor-based combinations for HR+/HER2-advanced breast cancer: A Bayesian network meta-analysis

Guo, XA; Zhou, YX; Zhang, K; Lu, W; Zhong, X; Wu, SJ; Shen, L; Chen, HH; Chen, YD

Chen, HH; Chen, YD (通讯作者)，Zhejiang Univ, Dept Breast Surg & Oncol, Key Lab Canc Prevent & Intervent, China Natl Minist Educ,Key Lab Mol Biol Med Sci,Af, Hangzhou, Zhejiang, Peoples R China.

JOURNAL OF EVIDENCE BASED MEDICINE, 2023; ():

Abstract

BackgroundInternational guidelines recommend cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)-based first-line therapy for hormone receptor-positive, h......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索